Filtered By:
Cancer: Squamous Cell Carcinoma
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 783 results found since Jan 2013.
Depletion of RIPK4 parallels higher malignancy potential in cutaneous squamous cell carcinoma
CONCLUSIONS: In general, although depletion of RIPK4 cannot reverse the radiation resistance of A431 cells in vitro, it parallels higher malignancy potential in cutaneous SCC. To our knowledge, this is the first report of the effects of RIPK4 expression on the Raf/MEK/ERK signaling pathway and radiosensitivity in cutaneous SCC. The better understanding of the molecular mechanism of RIPK4 in cutaneous SCC may provide a promising biomarker for skin SCC prognosis and treatment.PMID:35186499 | PMC:PMC8841032 | DOI:10.7717/peerj.12932
Source: Cancer Control - February 21, 2022 Category: Cancer & Oncology Authors: Jing Xu Dongping Wu Bicheng Zhang Chi Pan Yinglu Guo Qichun Wei Source Type: research
Oral squamous cell carcinoma–released brain-derived neurotrophic factor contributes to oral cancer pain by peripheral tropomyosin receptor kinase B activation
Oral cancer pain is debilitating and understanding mechanisms for it is critical to develop novel treatment strategies treatment strategies. Brain-derived neurotrophic factor (BDNF) signaling is elevated in oral tumor biopsies and is involved with tumor progression. Whether BDNF signaling in oral tumors contributes to cancer-induced pain is not known. The current study evaluates a novel peripheral role of BDNF-tropomyosin receptor kinase B (TrkB) signaling in oral cancer pain. Using human oral squamous cell carcinoma (OSCC) cells and an orthotopic mouse tongue cancer pain model, we found that BDNF levels were upregulated i...
Source: Pain - February 14, 2022 Category: Anesthesiology Tags: Research Paper Source Type: research
Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma < em > via < /em > the PI3K/AKT pathway
CONCLUSION: Our study suggests for the first time that DDX51 promotes cancer cell proliferation by regulating the PI3K/AKT pathway; thus, DDX51 might be a therapeutic target for ESCC.PMID:35125830 | PMC:PMC8790558 | DOI:10.3748/wjg.v28.i4.464
Source: World Journal of Gastroenterology - February 7, 2022 Category: Gastroenterology Authors: Dong-Xin Hu Qi-Feng Sun Lin Xu Hong-Da Lu Fan Zhang Zhen-Miao Li Ming-Yan Zhang Source Type: research
